ArticleFrontiers in pharmacology2026
Mangiferin alleviates metabolic-associated fatty liver disease by modulating gut microbiota and FXR signaling pathway to regulate bile acid metabolism.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic-associated fatty liver disease (MAFLD) is characterized by excessive hepatic lipid accumulation, with limited safe and effective therapeutic options currently available. Previous studies have demonstrated that mangiferin (MAN) alleviates nonalcoholic fatty liver disease via modulation of the AMPK and NLRP3 signaling pathways. However, there are no reports to date investigating whether MAN exerts anti-MAFLD effects by regulating bile acid (BAs) metabolism and its underlying molecular mechanisms. Methods: In the present study, the anti-MAFLD effects of MAN were systematically investigated using a high-fat diet (HFD)-induced MAFLD mouse model. We evaluated the therapeutic mechanisms of MAN specifically from the perspectives of BAs metabolism regulated by the farnesoid X receptor (FXR) signaling pathway and the modulation of the gut microbiota, utilizing 16S rRNA sequencing and molecular docking analyses. Results: MAN treatment (100 mg/kg) significantly ameliorated glucose and lipid metabolic disorders, as well as hepatic lipid accumulation in the HFD-induced MAFLD mice, which was accompanied by marked alterations in the BAs metabolic profile. Mechanistically, MAN activated the FXR signaling pathway, and molecular docking analysis predicted stable interactions with key FXR residues (Y365, M369, and Y373). Furthermore, 16S rRNA sequencing revealed that MAN significantly decreased the relative abundance of Conclusion: MAN exerts anti-MAFLD effects through dual mechanisms: direct activation of the FXR signaling pathway to regulate BAs homeostasis and indirect modulation of the gut microbiota to influence BAs metabolism. These findings highlight the therapeutic potential of MAN and provide new insights into natural product-based strategies for MAFLD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.